Literature DB >> 20658221

Successful treatment of South American rattlesnake (Crotalus durissus terrificus) envenomation with Crotalidae polyvalent immune Fab (CroFab™).

Michael J Lynch1, Seth C Ritter, Robert D Cannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20658221      PMCID： PMC3614103          DOI： 10.1007/s13181-010-0100-z

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


× No keyword cloud information.
  7 in total

Review 1.  Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom.

Authors:  L V Boyer; S A Seifert; J S Cain
Journal:  Ann Emerg Med       Date:  2001-02       Impact factor: 5.721

2.  A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States.

Authors:  R C Dart; S A Seifert; L V Boyer; R F Clark; E Hall; P McKinney; J McNally; C S Kitchens; S C Curry; G M Bogdan; S B Ward; R S Porter
Journal:  Arch Intern Med       Date:  2001-09-10

3.  Crotalidae polyvalent immune Fab (ovine) antivenom is effective in the neutralization of South American viperidae venoms in a murine model.

Authors:  William H Richardson; David A Tanen; Tri C Tong; David P Betten; Shaun D Carstairs; Saralyn R Williams; Frank L Cantrell; Richard F Clark
Journal:  Ann Emerg Med       Date:  2005-06       Impact factor: 5.721

4.  Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation.

Authors:  Anne-Michelle Ruha; Steven C Curry; Michael Beuhler; Ken Katz; Daniel E Brooks; Kimberlie A Graeme; Kevin Wallace; Richard Gerkin; Frank Lovecchio; Paul Wax; Brad Selden
Journal:  Ann Emerg Med       Date:  2002-06       Impact factor: 5.721

5.  Coagulopathy following lethal and non-lethal envenoming of humans by the South American rattlesnake (Crotalus durissus) in Brazil.

Authors:  I S Sano-Martins; S C Tomy; D Campolina; M B Dias; S C de Castro; M C de Sousa-e-Silva; C F Amaral; N A Rezende; A S Kamiguti; D A Warrell; R D Theakston
Journal:  QJM       Date:  2001-10

6.  Complications of Crotalidae antivenin therapy.

Authors:  G J Jurkovich; A Luterman; K McCullar; M L Ramenofsky; P W Curreri
Journal:  J Trauma       Date:  1988-07

7.  Sites of action of Mojave toxin isolated from the venom of the Mojave rattlesnake.

Authors:  P Gopalakrishnakone; B J Hawgood; S E Holbrooke; N A Marsh; S Santana De Sa; A T Tu
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739
  7 in total
  2 in total

1.  Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.

Authors:  Natalie E Stevens; Antoinette Hatjopolous; Cara K Fraser; Mohammed Alsharifi; Kerrilyn R Diener; John D Hayball
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

2.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.